Literature DB >> 6091484

Comparison of ceftriaxone and cefazolin prophylaxis against infection in open heart surgery.

T R Beam, T A Raab, J A Spooner, S C Balderman, J Aldridge, J N Bahyana.   

Abstract

One hundred four patients undergoing elective open heart surgery were enrolled in a prospective, double-blind trial comparing prophylaxis against infection using a single 1 g dose of ceftriaxone and seven doses of cefazolin. Patients in both groups had similar risk factors for infection. The likelihood of achieving a tissue concentration in excess of the minimal inhibitory concentration for Staph. aureus was significantly greater with ceftriaxone in atrial appendage (p less than 0.001), muscle (p less than 0.01), and bone (p less than 0.01) than with cefazolin. The serum half-life of ceftriaxone was approximately 15.7 hours. All 49 serum samples obtained 18 to 24 hours after delivery of ceftriaxone and 26 of 33 samples obtained 40 to 48 hours after delivery had drug concentrations in excess of 3.1 micrograms/ml, the mean minimal inhibitory concentration for isolates of Staph. aureus. Early and late infectious complications were infrequent and occurred at similar rates in both groups. Neither drug was associated with significant toxicity. A single 1 g dose of ceftriaxone was as effective and safe as multiple doses of cefazolin and demonstrated superior tissue penetration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091484

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

Review 1.  Reappraisal of the antistaphylococcal activities of first-generation (narrow-spectrum) and second-generation (expanded-spectrum) cephalosporins.

Authors:  L D Sabath
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

2.  In vitro activity of ceftriaxone and other cephalosporins against 602 clinical isolates of staphylococci from geographically diverse medical centers.

Authors:  M A Pfaller; A L Barry; L D Sabath; B N Kreiswirth; P R Murray; P C Fuchs; J C McLaughlin
Journal:  Eur J Epidemiol       Date:  1993-11       Impact factor: 8.082

Review 3.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

4.  Single-dose antimicrobial prophylaxis in open heart surgery.

Authors:  T Beam; T Raab; J Spooner; S Balderman; J Aldridge; J Bhayana
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

5.  A meta-analysis of randomized, controlled trials assessing the prophylactic use of ceftriaxone. A study of wound, chest, and urinary infections.

Authors:  J C Woodfield; N Beshay; A M van Rij
Journal:  World J Surg       Date:  2009-12       Impact factor: 3.352

6.  Ceftriaxone disposition in open-heart surgery patients.

Authors:  G L Jungbluth; M T Pasko; T R Beam; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

7.  Ceftriaxone versus Other Antibiotics for Surgical Prophylaxis : A Meta-Analysis.

Authors:  Silvano Esposito; Silvana Noviello; Alessandro Vanasia; Paola Venturino
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

8.  The effect of first- and third-generation prophylactic antibiotics on hospitalization and medical expenditures for cardiac surgery.

Authors:  Sung-Jin Bae; Inah Kim; Jaechul Song; Euy-Suk Chung
Journal:  J Cardiothorac Surg       Date:  2022-02-05       Impact factor: 1.637

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.